We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01613313
First Posted: June 7, 2012
Last Update Posted: October 6, 2016
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Advance Biofactures Corporation
Information provided by (Responsible Party):
Zachary Gerut, Gerut, Zachary, M.D.
Results First Submitted: February 10, 2016  
Study Type: Interventional
Study Design: Allocation: Non-Randomized;   Intervention Model: Single Group Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Lipoma
Intervention: Drug: Collagenase Clostridium Histolyticum

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Subjects were screened and enrolled at 1 site in the United States

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Dose #1

single injection 0.058 mg Collagenase Clostridium Histolyticum

Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Dose #2

single injection 0.15 mg Collagenase Clostridium Histolyticum

Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Dose #3

single injection 0.29 mg Collagenase Clostridium Histolyticum

Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Dose #4

single injection 0.44 mg Collagenase Clostridium Histolyticum

Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.


Participant Flow:   Overall Study
    Dose #1   Dose #2   Dose #3   Dose #4
STARTED   2   4   4   4 
COMPLETED   2   4   4   4 
NOT COMPLETED   0   0   0   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Dose #1

single injection 0.058 mg Collagenase Clostridium Histolyticum

Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Dose #2

single injection 0.15 mg Collagenase Clostridium Histolyticum

Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Dose #3

single injection 0.29 mg Collagenase Clostridium Histolyticum

Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Dose #4

single injection 0.44 mg Collagenase Clostridium Histolyticum

Collagenase Clostridium Histolyticum: This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.

Total Total of all reporting groups

Baseline Measures
   Dose #1   Dose #2   Dose #3   Dose #4   Total 
Overall Participants Analyzed 
[Units: Participants]
 2   4   4   4   14 
Age 
[Units: Years]
Mean (Standard Deviation)
 48.0  (5.66)   51.5  (12.50)   41.3  (11.09)   57.0  (4.97)   49.6  (10.60) 
Gender 
[Units: Participants]
         
Female   2   3   3   1   9 
Male   0   1   1   3   5 
Region of Enrollment 
[Units: Participants]
         
United States   2   4   4   4   14 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Change in Visible Surface Area of the Lipoma   [ Time Frame: Baseline and Six months post injection of study drug ]

2.  Secondary:   Relative Change in Volume of the Lipoma   [ Time Frame: Baseline and 6 months post injection of study drug ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.
The agreement is:
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.
unchecked The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.


Results Point of Contact:  
Name/Title: Dr. Zachary E.Gerut
Organization: GerutZ
phone: 516 295-2100
e-mail: Drgerut@drgerut.com



Responsible Party: Zachary Gerut, Gerut, Zachary, M.D.
ClinicalTrials.gov Identifier: NCT01613313     History of Changes
Other Study ID Numbers: Lipoma DE/01
First Submitted: June 5, 2012
First Posted: June 7, 2012
Results First Submitted: February 10, 2016
Results First Posted: March 9, 2016
Last Update Posted: October 6, 2016